Dr Christopher Coxon School of Pharmacy, LJMU

Liverpool, United Kingdom

**********************************************************************************************

We have a new PhD studentship available to start immediately (click here for details!)

The project involves developing new methods for the synthesis of cyclic, multicyclic and stapled peptides to target cancer and muscle-wasting diseases.

*************************************************************************************************

In 2013 Christopher began his independent research career as a temporary lecturer at Durham University, before being appointed to the position of Lecturer in Medicinal and Natural Products Chemistry at Liverpool John Moores University in October 2014.

Research Interests:

The themes underpinning our Group's interests are of a multidisciplinary nature and fall broadly under the umbrella of biological and medicinal chemistry. I am specifically involved in the synthesis and application of peptides as chemical probes to understand cellular signaling through protein-protein interactions (PPIs). Key areas of interest are in targeting specific PPIs that are causative or instrumental in the development and propagation of cancer.

Anti-Cancer Stapled Peptides

Peptides are a class of therapeutic agent, which have received growing attention in recent years from academia and the pharmaceutical industry alike. They have the potential to treat previously ‘undruggable’ diseases e.g. types of cancer as well as infectious disease and inflammation, as they fill the chemical space between small molecules and large biomacromolecules (e.g. antibodies), combining the advantages of each.In one project, we are developing alternative technologies for peptide stapling - a method of taking a linear peptide and making it cyclic. This makes peptides resistant to breakdown within a patient, thereby making them more effective medicines and leading to new ways to treat life-threatening and debilitating illnesses. We are using these methods as part of an anti-cancer drug discovery programme aimed at disrupting the p53-MDM2/MDMX protein-protein interaction in collaboration with scientists at the Northern Institute for Cancer Research, Newcastle University.

  • Work
    • John Moores University